Unknown

Dataset Information

0

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.


ABSTRACT: BACKGROUND: Only 40-70% of metastatic colorectal cancers (mCRCs) with wild-type (WT) KRAS oncogene respond to anti-epidermal growth factor receptor (anti-EGFR) antibody treatment. EGFR amplification has been suggested as an additional marker to predict the response. However, improved methods for bringing the EGFR analysis into routine laboratory are needed. METHODS: The material consisted of 80 patients with mCRC, 54 of them receiving anti-EGFR therapy. EGFR gene copy number (GCN) was analysed by automated silver in situ hybridisation (SISH). Immunohistochemical EGFR protein analysis was used to guide SISH assessment. RESULTS: Clinical benefit was seen in 73% of high (≥ 4.0) EGFR GCN patients, in comparison with 59% of KRAS WT patients. Only 20% of low EGFR GCN patients responded to therapy. A high EGFR GCN number associated with longer progression-free survival (P<0.0001) and overall survival (P=0.004). Together with KRAS analysis, EGFR GCN identified the responsive patients to anti-EGFR therapy more accurately than either test alone. The clinical benefit rate of KRAS WT/high EGFR GCN tumours was 82%. CONCLUSION: Our results show that automated EGFR SISH, in combination with KRAS mutation analysis, can be a useful and easily applicable technique in routine diagnostic practise for selecting patients for anti-EGFR therapy.

SUBMITTER: Algars A 

PROVIDER: S-EPMC3142805 | biostudies-other | 2011 Jul

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC4062406 | biostudies-literature
| S-EPMC6173768 | biostudies-literature
| S-EPMC3593567 | biostudies-other
| S-EPMC3447654 | biostudies-literature
| S-EPMC4694911 | biostudies-literature
| S-EPMC3635875 | biostudies-other
| S-EPMC4121784 | biostudies-other
| S-EPMC8073594 | biostudies-literature
| S-EPMC4350801 | biostudies-literature
2018-10-26 | GSE121805 | GEO